Keir Starmer is facing calls from MPs to scrap a controversial healthcare agreement dubbed the “Trump tax” deal and redirect funds towards repairing the ailing social care system in Britain. The Liberal Democrats have criticized the Prime Minister for allegedly succumbing to pressure from the US President in striking the trade deal, which is projected to significantly increase pharmaceutical costs. Despite the Government’s defense of the agreement, concerns remain about the potential impact on medicine prices.
Pressure is mounting on the Prime Minister to expedite reforms in social care, with data revealing prolonged hospital stays for patients who could be better cared for elsewhere. The delay in addressing these issues has sparked criticism from Lib Dem deputy leader Daisy Cooper, who urged Starmer to prioritize fixing social care over honoring the trade agreement.
While the Government had initiated a commission on social care in early 2021, progress has been slow, drawing further reproach. The opposition parties, particularly Labour, have pledged to establish a new National Care Service, with recommendations expected from Baroness Louise Casey’s commission in the near future.
Amidst the ongoing debate, concerns persist about the impact of the UK-US agreement on healthcare costs. The Lancet journal has estimated a substantial increase in drug expenses annually, a claim contested by the Government, which emphasizes the benefits of the deal for securing medicine supplies and enhancing trade terms in the medical technology sector.
Responding to criticisms, a government spokesperson refuted the notion of diverting funds from NHS services and asserted the deal’s importance in bolstering the healthcare sector. Efforts are underway to streamline hospital discharge processes and improve coordination between healthcare and social care services to mitigate delays and enhance patient care.
In a statement, Robert F. Kennedy, Jr., representing the US side, lauded the agreement as a positive step towards promoting innovation in the pharmaceutical industry and rebalancing trade relations. The UK government remains committed to addressing both the social care crisis and healthcare challenges while emphasizing the collaborative efforts to enhance patient care and support NHS services.